Aquestive therapeutics presented positive topline phase 1 results for aqst-109 epinephrine oral film at american academy of allergy, asthma, and immunology (aaaai) annual meeting

Warren, n.j., feb. 28, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, presented a late breaking poster recapping positive topline data from a phase 1 pharmacokinetic study of aqst-109 epinephrine oral film at the american academy of allergy, asthma, and immunology (aaaai) annual meeting, which was held from february 25-28 in phoenix, arizona.
AQST Ratings Summary
AQST Quant Ranking